Alembic Pharma’s JV gets USFDA’s nod for Clobetasol Propionate Topical Solution

22 Oct 2019 Evaluate

Alembic Pharmaceuticals’ joint venture (JV) Aleor Dermaceuticals (Aleor) has received approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Clobetasol Propionate Topical Solution USP, 0.05%. The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD) Temovate Topical Solution, 0.05%, of Fougera Pharmaceuticals Inc. (Fougera). Clobetasol Propionate Topical Solution USP, 0.05% is indicated for short-term topical treatment of inflammatory and pruritic manifestations of moderate to severe corticosteroid-responsive dermatoses of the scalp. 

Clobetasol Propionate Topical Solution USP, 0.05%, has an estimated market size of $33 million for twelve months ending December 2018 according to IQVIA. Alembic has a cumulative total of 104 ANDA approvals (92 final approvals and 12 tentative approvals) from USFDA.

Alembic Pharmaceuticals, a vertically integrated research and development pharmaceutical company, has been at the forefront of Healthcare since 1907.

Alembic Pharma Share Price

756.75 -5.80 (-0.76%)
27-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1639.30
Dr. Reddys Lab 1240.00
Cipla 1312.85
Zydus Lifesciences 893.45
Lupin 2147.60
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×